Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 348 participants.
Also called NCT02390375
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 348 participants
- Registry
-
NCT02390375
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02390375. Randomized; double masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- DW-0929
- Intervention (Drug)
- DW-0929
- Intervention (Drug)
- DW-0929
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Rosuvastatin
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02390375- Content hash
a2cca0a7a401a6ae96bbfd54ae1e02067c86329487136397cdc62e6045c38ad9